ADT™ Booster is used for primary and booster vaccination of children 7 years of age and over and adults to protect against tetanus and diphtheria. An alternative vaccine called Boostrix®, which protects against tetanus, diphtheria and pertussis (whooping cough), can be substituted for one, two or all three doses of the primary vaccinations in these age groups. Both ADT™ Booster and Boostrix® are licensed as booster vaccines. They are used for primary vaccination out of licensure as there is no alternative primary vaccination strength vaccine available in New Zealand for these age groups. When the vaccine is used for a primary vaccination course, use will be outside of current licensure. No safety concerns are expected with use in these circumstances.
Infanrix®-IPV is used for primary and booster vaccination of infants and children to protect against diphtheria, tetanus, pertussis and poliomyelitis. Infanrix®-IPV can also be used for catch-up immunisation for children up to their 10th birthday.
Boostrix® is used for booster vaccination of adolescents aged 11 years and pregnant women between 28-38 weeks gestation* to protect against diphtheria, tetanus and pertussis (whooping cough). Boostrix® can also be used for catch-up immunisation for children aged 7 years# to under 18 years.
*After immunisation protection against pertussis takes up to two weeks to develop. Whilst immunisation between 38-40 weeks gestation is still safe for mother and baby later immunisation means the newborn may still be exposed to the disease by their mother on delivery and/or during the first two weeks of life. The PHARMAC decision to limit funded Boostrix® to 28-38 weeks gestation maximises the benefit of immunisation against pertussis whilst being accountable for the use of public funds. Pregnant women can choose to purchase Boostrix® privately after 38 weeks gestation or at any time after delivery.
#Although Boostrix® is not licensed for use in children aged 7 years to under 10 years it has been used in New Zealand and overseas in this age group and there are no safety concerns with off-label use.